SCHEMBL1373976

SCHEMBL1373976

NOC(=O)CCC(N)C(=O)ON

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.38
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GSR P00390 1/20 0.38
CYP1A2 P05177 1/20 0.38
GRIK1 P39086 1/20 0.38
GRM5 P41594 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
GRIA4 P48058 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIK2 Q13002 1/20 0.38
GRIK3 Q13003 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648219 1.00 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL3510151 1.00 SLC1A1 (0.38) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL21002223 0.87 GSR (0.33) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL2723398 0.85 SLC1A1 (0.51) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL29831114 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL22502695 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL5496875 0.82 GRM8 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL167845 0.82 ALOX15 (0.58) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL8697 0.82 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL17724321 0.82 SLC1A1 (0.60) SLC1A1GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200270202-A1 POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE THE UNIVERSITY OF TOLEDO (US) 2020-08-27 US claimed
WO-2017172476-A1 POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE THE UNIVERSITY OF TOLEDO (US) 2017-10-05 WO claimed
EP-2661493-B1 PLASMINOGEN AND PLASMIN VARIANTS THROMBOGENICS NV (BE) 2016-03-30 EP claimed
EP-2661493-A1 PLASMINOGEN AND PLASMIN VARIANTS ThromboGenics N.V. (BE) 2013-11-13 EP claimed
US-20130273028-A1 PLASMINOGEN AND PLASMIN VARIANTS THROMBOGENICS NV (BE) 2013-10-17 US claimed
WO-2012093132-A1 PLASMINOGEN AND PLASMIN VARIANTS THROMBOGENICS NV (BE) 2012-07-12 WO claimed
US-20060058221-A1 Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders MILLER LANDON C 2006-03-16 US claimed
WO-2024118297-A1 BIOPROSTHETIC TISSUE AND PROSTHETIC ANTIMICROBIAL TREATMENT EDWARDS LIFESCIENCES CORPORATION (US) 2024-06-06 WO disclosed
US-20230240966-A1 COMPOSITIONS AND METHODS FOR TREATING HAIR FOLLICLE-LINKED CONDITIONS HENLEZ APS (DK) 2023-08-03 US disclosed
EP-4171237-A1 USE OF AN ORGANO-MINERAL COMPOSITION VIA FOLIAR APPLICATION TO STIMULATE PLANT DEVELOPMENT IN THE PRESENCE OF AT LEAST ONE ABIOTIC STRESS OR BIOTIC STRESS Olmix (FR) 2023-05-03 EP disclosed
US-20230104647-A1 METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS IMAGO BIOSCIENCES, INC. 2023-04-06 US disclosed
CN-111182911-B Composition for protecting retinal nerve cells comprising processed product of cowberry fruit and processed product of pine bark 参天制药株式会社 2023-04-04 CN disclosed
EP-4135755-A1 COMPOSITIONS AND METHODS FOR TREATING HAIR FOLLICLE-LINKED CONDITIONS Henlez ApS (DK) 2023-02-22 EP disclosed
WO-2005004897-A1 WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS VION PHARMACEUTICALS, INC. (US) 2005-01-20 WO disclosed
US-20040254103-A1 WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS NANOSHIFT, LLC 2004-12-16 US disclosed
US-20020169125-A1 Fusion protein such as of polyglutamic acid and interferon-alpha; improves bioactivity and water-solubility properties of a drug to which it is conjugated CELL THERAPEUTICS, INC. 2002-11-14 US disclosed
WO-2002077036-A2 RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS, AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2002-10-03 WO disclosed
US-6444644-B1 PEPTIDE HAVING SPECIFIED AMINO ACID SEQUENCE; USED FOR INHIBITION OF THROMBOPLASTIN UNIVERSITY COLLEGE LONDON (GB) 2002-09-03 US disclosed
EP-0917539-A1 ANTICOAGULANT PEPTIDE FRAGMENTS DERIVED FROM APOLIPOPROTEIN B-100 UNIVERSITY COLLEGE LONDON (GB) 1999-05-26 EP disclosed
WO-1997043311-A1 ANTICOAGULANT PEPTIDE FRAGMENTS DERIVED FROM APOLIPOPROTEIN B-100 UNIVERSITY COLLEGE LONDON (GB) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104647-A1 METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS KDM1A, KDM1B, KDM2A SLC1A1 3968/4885GRM8 3103/4885GRM6 3535/4885
US-20200270202-A1 POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE GOT1, ACAT1, GOT2 SLC1A1 268/4885GRM8 4111/4885GRM6 3615/4885
US-20040254103-A1 WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS SHPRH, OGFR, COG3 SLC1A1 459/4885GRM8 107/4885GRM6 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.